The inability to provide consistently safe and effective relief underscores the pressing need for alternative therapies, making corticosteroid limitations a key restraint in the ischemic optic neuropathy treatment market
By lowering appetite and controlling hunger, semaglutide can help people lose weight
GLP-1 Bridge is a workaround, since it operates outside the Part D benefit, runs on CMSs demonstration authority, and expires on December 31, 2027
No insurance barriers Simple, direct access to treatment without approvals, denials, or delays
While semaglutide and liraglutide can be powerful weight loss tools, people see the best results when they use the medication as part of a healthy, active lifestyle and careful food intake
While the mechanisms of action for these drugs are similar, they each work in slightly different ways